Patients with TNBC had significantly worse median post-LMD OS (2 months, [1.1, 3.4]), when compared to both patients with HER2 + (8.4 months [6.5, 14.5]; p = 0.0016) and HR + BC (5.3 months, [2.9, 9.3]; p = 0.0097). The gene discussed is ERBB2; the disease is breast cancer.